1-(4-aminophenyl)-2-(3,4,5-trimethoxyphenyl)ethane | 110997-90-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-(4-aminophenyl)-2-(3,4,5-trimethoxyphenyl)ethane
• 英文别名: 4-(3,4,5-trimethoxyphenethyl)aniline；4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenylamine；4-[2-(3,4,5-Trimethoxyphenyl)ethyl]benzenamine；4-[2-(3,4,5-trimethoxyphenyl)ethyl]aniline
• CAS: 110997-90-5
• 化学式: C₁₇H₂₁NO₃
• 分子量: 287.359
• InChiKey: BPIQFCQFIYIISU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  53.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-aminophenyl)-2-(3,4,5-trimethoxyphenyl)ethane 、 乙酰氯 在 三乙胺 作用下， 以 苯 为溶剂， 生成 1-(4-acetamidophenyl)-2-(3,4,5-trimethoxyphenyl)ethane
  参考文献：
  名称：

  Stilbene derivatives as anticancer agents

  摘要：

  本发明涉及一种具有抗癌作用的苯乙烯衍生物。这些化合物可用于治疗易于通过其治疗的癌症，并可用于治疗这些癌症的方法中。本文还披露了含有这些化合物的制药组合物。在披露的化合物中，有三种优选的化合物，分别为(Z)-1-(4-甲氧基苯基)-2-(3,4,5-三甲氧基苯基)乙烯，(Z)-1-(4-甲基苯基)-2-(3,4,5-三甲氧基苯基)乙烯和4-甲基-3',4',5'-三甲氧基苯乙胺盐酸盐。

  公开号：

  US05430062A1
• 作为产物：
  描述：

  1,2,3-trimethoxy-5-[2-(4-nitrophenyl)vinyl]benzene 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 以90%的产率得到1-(4-aminophenyl)-2-(3,4,5-trimethoxyphenyl)ethane
  参考文献：
  名称：

  Inhibition of Restriction Enzymes EcoRI, BamHI and HindIII by Phenethylphenylphthalimides Derived from Thalidomide

  摘要：

  我们通过筛选具有苯乙基苯基邻苯二甲酰亚胺骨架的化合物库，发现了限制酶 EcoRI、BamHI 和 HindIII 的抑制剂，这些化合物的基础是来自沙利度胺的α-葡萄糖苷酶抑制剂和肝 X 受体拮抗剂。通过结构开发，获得了强效限制酶抑制剂 25 和 26。

  DOI：

  10.1248/cpb.59.880
• 作为试剂：
  描述：

  1,2,3-trimethoxy-5-[2-(4-nitrophenyl)vinyl]benzene 在 镍 1-(4-aminophenyl)-2-(3,4,5-trimethoxyphenyl)ethane 、 氢气 作用下， 以 四氢呋喃 为溶剂， 21.0~26.0 ℃ 、8.82 MPa 条件下， 以This procedure yielded a tan powder, 6.6 g (0.023 mol, 74%) of the desired product的产率得到1-(4-aminophenyl)-2-(3,4,5-trimethoxyphenyl)ethane
  参考文献：
  名称：

  Method of inhibiting amyloid protein aggregation and imaging amyloid deposits

  摘要：

  本发明提供了一种利用I式化合物治疗阿尔茨海默病的方法。同时，本发明还提供了一种利用I式化合物抑制淀粉样蛋白聚集的方法，以及一种成像淀粉样沉积物的方法，以及新的I式化合物。

  公开号：

  US20040220235A1

文献信息

• Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0221345A1

  公开（公告）日：1987-05-13

  The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.

  本发明涉及新型烯酰胺类化合物、药物组合物及其使用方法，可用于治疗脂氧合酶酶活性产物或白三烯作用导致病理状态的疾病。
• Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer
  作者：Bin Sun、Juma Hoshino、Katie Jermihov、Laura Marler、John M. Pezzuto、Andrew D. Mesecar、Mark Cushman

  DOI：10.1016/j.bmc.2010.05.042

  日期：2010.7

  A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 mu M) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 mu M. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC50 1.7 mu M and 0.27 mu M, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer. (C) 2010 Elsevier Ltd. All rights reserved.
• Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization
  作者：Mark Cushman、Dhanapalan Nagarathnam、D. Gopal、Asit K. Chakraborti、Chii M. Lin、Ernest Hamel

  DOI：10.1021/jm00112a036

  日期：1991.8

  An array of cis-, trans-, and dihydrostilbenes and some N-arylbenzylamines were synthesized and evaluated for their cytotoxicity in the five cancer cell cultures A-549 lung carcinoma, MCF-7 breast carcinoma, HT-29 colon adenocarcinoma, SKMEL-5 melanoma, and MLM melanoma. Several cis-stilbenes, structurally similar to combretastatins, were highly cytotoxic in all five cell lines and these were also found to be active as inhibitors of tubulin polymerization. The most active compounds also inhibited the binding of colchicine to tubulin. The most potent of the new compounds, both as a tubulin polymerization inhibitor and as a cytotoxic agent, was (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene (5a). This substance was almost as potent as combretastatin A-4 (1a), the most active of the combretastatins, as a tubulin polymerization inhibitor. Compound 5a was found to be approximately 140 times more cytotoxic against HT-29 colon adenocarcinoma cells and about 10 times more cytotoxic against MCF-7 breast carcinoma cells than combretastatin A-4. However, 5a was found to be about 20 times less cytotoxic against A-549 lung carcinoma cells, 30 times less cytotoxic against SKMEL-5 melanoma cells, and 7 times less cytotoxic against MLM melanoma cells than combretastatin A-4. The relative potencies 5a > 8a > 6a for the cis, dihydro, and trans compounds, respectively, as inhibitors of tubulin polymerization are in agreement with the relative potencies previously observed for combretastatin A-4 (1a), dihydrocombretastatin A-4 (1c), and trans-combretastatin A-4 (1b). The relative potencies 5a > 8a > 6a were also reflected in the results of the cytotoxicity assays. Structure-activity relationships of this group of compounds are also discussed.
• (N-substituted-2-hydroxy) benzamides and N-substituted-2-hydroxy-alpha-oxo-benzeneacetamides and pharmaceutical compositions thereof having activity as modulators of the arachidonic acid cascade
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0221346B1

  公开（公告）日：1991-01-30
• CARETHERS, MARY E.;CETENKO, WIACZESLAW A.;CONNOR, DAVID T.;JOHNSON, ELIZA+
  作者：CARETHERS, MARY E.、CETENKO, WIACZESLAW A.、CONNOR, DAVID T.、JOHNSON, ELIZA+

  DOI：——

  日期：——